Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Melanoma 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Pancreatic Neoplasms 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-cell Malignancies 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 12fludarabine 10fludarabine phosphate 7Radiotherapy 6Mycophenolic Acid 6Whole-Body Irradiation 5Sirolimus 5Filgrastim 5Tacrolimus 4Melphalan 4Busulfan 4Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Cyclosporine 3Thiotepa 2Stem Cell Transplantation 2Specimen Handling 2Rituximab 2Methotrexate 2Mesna 2Granulocyte Colony-Stimulating Factor 2Etoposide 2venetoclax 1siplizumab 1rasburicase 1prostaglandin D2 receptor 1milatuzumab 1itacitinib 1eritoran 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Graft vs Host Disease × INCB039110 × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡